Daiichi Sankyo Initiates Clinical Trial with its 4th DXd Antibody Drug Conjugate, DS-7300, in Collaboration with Sarah Cannon Research Institute
First-in-human phase 1/2 study evaluating DS-7300, a B7-H3 targeting ADC, in patients with advanced/unresectable or metastatic solid tumors B7-H3 is a protein overexpressed in various...